MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-30-2026
Precipio Retained Earnings 2011-2026 | PRPO
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Precipio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -103 M | -102 M | -98.2 M | -92.3 M | -80.1 M | -71.6 M | -60.9 M | -47.7 M | -31.5 M | -225 M | -213 M | -184 M | -169 M | -152 M | -143 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -31.5 M | -225 M | -118 M |
Quarterly Retained Earnings Precipio
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -103 M | -103 M | -103 M | -102 M | -102 M | -101 M | -100 M | -98.2 M | -99.1 M | -97.6 M | -95.3 M | -92.3 M | -90 M | -86.8 M | -84.7 M | -80.1 M | -77.9 M | -76 M | -73 M | -71.6 M | -71.6 M | -71.6 M | -71.6 M | -60.9 M | -60.9 M | -60.9 M | -60.9 M | -47.7 M | -47.7 M | -47.7 M | -47.7 M | -31.5 M | -31.5 M | -31.5 M | -31.5 M | -10.8 M | -10.8 M | -10.8 M | -225 M | -213 M | -213 M | -213 M | -213 M | -184 M | -184 M | -184 M | -184 M | -169 M | -169 M | -169 M | -169 M | -152 M | -152 M | -152 M | -152 M | -143 M | -143 M | -143 M | -143 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -10.8 M | -225 M | -107 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
348 M | $ 114.84 | -0.55 % | $ 34.9 B |  USA |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M |  Israel |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
-252 M | $ 2.59 | 1.37 % | $ 84.1 K | USA |
|
Biodesix
BDSX
|
-462 M | $ 15.32 | 1.66 % | $ 1.99 B | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.17 | - | $ 4.98 M | USA |
 |
BioNano Genomics
BNGO
|
-720 M | $ 1.19 | -1.25 % | $ 6.48 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 16.57 | 2.28 % | $ 178 M | China |
 |
CareDx, Inc
CDNA
|
-735 M | $ 18.37 | 0.33 % | $ 979 M | USA |
 |
Celcuity
CELC
|
-449 M | $ 113.92 | 1.14 % | $ 5.33 B | USA |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 167.82 | -3.49 % | $ 8.32 B | USA |
 |
Castle Biosciences
CSTL
|
-200 M | $ 24.95 | 0.44 % | $ 693 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 198.98 | 0.92 % | $ 22.1 B | USA |
 |
Danaher Corporation
DHR
|
46.9 B | $ 191.91 | 0.41 % | $ 137 B | USA |
 |
DexCom
DXCM
|
2.43 B | $ 63.19 | 1.56 % | $ 24.7 B | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Fulgent Genetics
FLGT
|
590 M | $ 16.66 | -0.95 % | $ 504 M | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 90.61 | -3.44 % | $ 11.4 B | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 111.56 | -2.31 % | $ 9.2 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 1.96 | 5.82 % | $ 8.67 M | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 128.04 | 0.52 % | $ 20.4 B | USA |
 |
IQVIA Holdings
IQV
|
7.42 B | $ 171.32 | -1.12 % | $ 29.4 B | USA |
 |
Invitae Corporation
NVTA
|
-4.83 B | - | - | $ 21.2 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 275.75 | 0.74 % | $ 22.9 B | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 76.36 | 0.35 % | $ 5.15 B | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 490.0 | -1.67 % | $ 14.1 B | USA |
 |
Organovo Holdings
ONVO
|
-342 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
-294 M | - | -16.95 % | $ 1.54 M | USA |
 |
Mettler-Toledo International
MTD
|
9.24 B | $ 1 257.33 | -0.21 % | $ 25.9 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 4.78 | 0.63 % | $ 443 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-110 M | $ 4.51 | -3.84 % | $ 3.55 M | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 8.0 | - | $ 1.02 B | USA |